Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Oxyphenonium is an antagonist of muscarinic acetylcholine receptors that binds to muscarinic receptors on isolated guinea pig atria and ileum (Kds = 0.11 and 0.17 nM, respectively).1 In vivo, oxyphenonium reverses carbaminocholine- and acetylcholine-induced decreases in blood pressure in anesthetized cats (ED50s = 0.591 and 1 μg/kg, respectively).2 It decreases rumenal ulcer formation in rats and suppresses insulin-induced gastric secretion in dogs with gastric fistulas.3 Oxyphenonium also prevents form-deprivation myopia (FDM) in a chick model of experimental myopia.4 Formulations containing oxyphenonium have been used to treat peptic ulcers.
WARNING This product is not for human or veterinary use.
1. Competitive and non-
2. Comparative quantitative studies on cholinolytics. 3. The action of propanteline, methanteline, oxyphenonium and diphemanil. Arch. Immunol. Ther. Exp. (Warsz.) 18(1), 139-142 (1970).
3. Inhibition of ulcer formation in the Shay rat and reduction of gastric acidity in dogs by antrenyl (oxyphenonium) (BA5473) diethyl(2-
4. Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. Invest. Ophthalmol. Vis. Sci. 44(3), 1330-1338 (2003).